Title
Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years
Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial
Phase
Phase 2/Phase 3Lead Sponsor
Chaitanya HospitalStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Cerebral PalsyIntervention/Treatment
Intra thecal inj of autologous MNCStudy Participants
100This Study is Single arm, Single Centre trail to check the safety and efficacy of bone marrow derived autologous mononuclear cells(100 millions per dose )trial to be conducted for 36 months in 100 patients ( below 15 years of age) with cerebral palsy in India. Primary outcome measures are improvement in walking ability and kinetic gait pattern.
This Study is Single arm, Single Centre trail to check the safety and efficacy of bone marrow derived autologous mononuclear cells(100 millions per dose )trial to be conducted for 36 months in 100 patients ( below 15 years of age) with cerebral palsy in India. Primary outcome measures are improvement in walking ability and kinetic gait pattern
Intra thecal inj of autologous MNC
Intra thecal inj of autologous MNC
Inclusion Criteria: Subject aged above 3 years and below 15 years with a diagnosis of Cerebral Palsy. Regional Nerve damage as shown by Magnetic Resonance Imaging(MRI) Able to Comprehend and give written informed consent form for the study willing to come to the hospital for follow up visits as per the protocol requirements Exclusion Criteria: History of meningitis,meningoencephalits,epilepsy or life threatening allergic or immune -mediated reaction 2 Hemodynamically unstable patients history of or concurrent autoimmune disease or acute episode if Guillain- barre syndrome peripheral Muscular dystropy